三例转移性前列腺癌对卡铂异常应答的基因组分析揭示不同类型DNA修复缺陷
Genomic Analysis of Three Metastatic Prostate Cancer Patients with Exceptional Responses to Carboplatin Indicating Different Types of DNA Repair Deficiency.
PubMed 文献 · Eur Urol · 2018-10-16
铂类方案尚未被证实可延长晚期前列腺癌生存,但部分前列腺癌存在同源重组DNA修复缺陷,此类基因组异常与PARP抑制及铂类具有合成致死效应。本文报告三例具有HRD缺陷的晚期去势抵抗性前列腺癌患者,均对卡铂表现出异常应答。
要点
- 部分晚期前列腺癌存在同源重组DNA修复缺陷。
- HRD缺陷与PARP抑制及铂类存在合成致死关系。
- 三例HRD缺陷去势抵抗性前列腺癌对卡铂异常应答。
核心结论
- 具有HRD缺陷的晚期去势抵抗性前列腺癌患者可能对卡铂产生异常应答。
研究设计与样本
- 本文为三例晚期去势抵抗性前列腺癌患者的病例报告及基因组分析。
主要发现
- 三例具有HRD缺陷的晚期去势抵抗性前列腺癌患者对卡铂表现出异常应答。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Platinum-based regimens have not been proved to increase survival from advanced prostate cancer (PCa). Incontrovertible evidence that a proportion of prostate cancers have homologous recombination DNA (HRD) repair defects, and that such genomic aberrations are synthetically lethal with both poly(ADP)-ribose polymerase inhibition and platinum, has increased interest in the utilisation of these drugs against a subset of these diseases. Here in we report three patients with advanced castration-resistant PCa with HRD defects having exceptional responses to carboplatin.
来源:Eur Urol,查看原文。版权归原作者所有。
引用
- Zafeiriou Z, Bianchini D, Chandler R, et al. Genomic Analysis of Three Metastatic Prostate Cancer Patients with Exceptional Responses to Carboplatin Indicating Different Types of DNA Repair Deficiency. Eur Urol. 2018. PMID: 30340782. doi:10.1016/j.eururo.2018.09.048
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。